

CITATION REPORT

List of articles citing

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

DOI: 10.7326/0003-4819-131-2-199907200-00002
Annals of Internal Medicine, 1999, 131, 81-7.

Source: <https://exaly.com/paper-pdf/31075000/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
659	Choosing the best initial therapy for HIV-1 infection. 1999 , 341, 1925-6		16
658	HIV. See a pocket, block it. 1999 , 401, 759		5
657	Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors. 1999 , 22, 453-60		17
656	Efavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1 Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease Inhibitors. 1999 , 22, 453		17
655	Erratum. 2000 , 8, 100-105		
654	Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. 2000 , 23, 236-45		62
653	Interaction of Methadone with Didanosine and Stavudine. 2000 , 24, 241-248		30
652	The role of observational studies in assessing the impact of antiviral therapies. 2000 , 13, 631-635		2
651	Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. 2000 , 14, 821-6		61
650	A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. 2000 , 14, 1171-80		67
649	A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). 2000 , 14, 1591-600		68
648	Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. 2000 , 14, 2247-55		70
647	Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. 2000 , 14, 357-66		767
646	Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. 2000 , 12, 438-44		14
645	Achieving plasma HIV RNA below the level of detection in clinical practice. 2000 , 5, 100-105		
644	The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. 2000 , 14, 2543-52		25
643	Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators. 2000 , 14, 491-7		14

642	Predictive value of the ultrasensitive HIV viral load assay in clinical practice. 2000 , 61, 411-6		6
641	Adherence and health care utilization in HIV/AIDS-rational or rationalizing?. <i>Journal of General Internal Medicine</i> , 2000 , 15, 891-3	4	6
640	The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. 2000 , 6, 82-5		398
639	New targets for inhibitors of HIV-1 replication. 2000 , 1, 40-9		142
638	Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients. 2000 , 41, 50-4		37
637	Healthcare Economics in HIV. 2000 , 2, 371-375		
636	Women and HIV--revisited ten years on. 2000 , 11, 277-83		8
635	The case for more cautious, patient-focused antiretroviral therapy. <i>Annals of Internal Medicine</i> , 2000 , 132, 306-11	8	48
634	Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study. 2000 , 23, 236-245		79
633	Interaction of Methadone with Didanosine and Stavudine. 2000 , 24, 241-248		51
632	Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. 2000 , 95, 457-62		92
631	Protease inhibitor therapy in HIV-infected children. 2000 , 14, 589-93		12
630	A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. 2000 , 97, 5639-44		387
629	Skepticism: a lost clinical art. 2000 , 31, 513-8		8
628	Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. 2000 , 31, 987-94		16
627	Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. 2000 , 44, 2672-8		83
626	Update on highly active antiretroviral therapy: progress and strategies. 2000 , 54, 7-12		23
625	Hit HIV-1 hard, but only when necessary. 2000 , 355, 2147-52		89

624	Adverse effects of antiretroviral therapy. 2000 , 356, 1423-30	880
623	Antiretroviral therapy in the year 2000. 2000 , 14, 827-49	7
622	Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. 2000 , 115, 118	1
621	Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing. 2000 , 14, 879-99	5
620	Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. 2000 , 14, 901-28	38
619	Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management. 2001 , 120, 607-21	39
618	The cost effectiveness of combination antiretroviral therapy for HIV disease. 2001 , 344, 824-31	388
617	Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. 2001 , 344, 472-80	596
616	SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. 2001 , 98, 12718-23	303
615	Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. 2001 , 98, 15161-6	121
614	[Current antiretroviral therapy]. 2001 , 22, 42-52	2
613	Symptômes ressentis après initiation d'une trithérapie avec inhibiteur de protéase et retentissement sur l'observance quatre mois après le début du traitement. 2001 , 31, 678-680	1
612	Predictors of protease inhibitor-associated adverse events. 2001 , 55, 321-3	13
611	Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. 2001 , 54 Suppl 1, S91-8	105
610	Does plasma HIV RNA predict outcome in a cohort of treated HIV-infected individuals followed over 3 years?. 2001 , 22, 271-8	3
609	Immunomodulators as adjunctive therapy for HIV-1 infection. 2001 , 22, 289-95	23
608	Impact of HAART on the clinical management of AIDS-related cancers. 2001 , 37, 1320-4	43
607	[Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy]. 2001 , 117, 607-10	7

606	Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. 2001 , 19, 1199-208	5
605	Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. 2001 , 27, 143-52	40
604	Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. 2001 , 15, 1115-23	137
603	Primary Care of the HIV-Infected Patient. 2001 , 4, 142-153	
602	Pharmacokinetic and other drug interactions in patients with AIDS. 2001 , 23, 591-605	42
601	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. 2001 , 15, 591-9	16
600	Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment?. 2001 , 15, 153-9	18
599	Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. 2001 , 15, 2109-17	162
598	Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study. 2001 , 2, 438-44	18
597	Antiretroviral Regimen Complexity, Self-Reported Adherence, and HIV Patients' Understanding of Their Regimens: Survey of Women in the HER Study. 2001 , 28, 124-131	118
596	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. 2001 , 15, 1701-6	49
595	Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. 2001 , 15, 117-9	12
594	Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. 2001 , 91, 1456-63	43
593	Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 Infection. 2001 , 27, 251-259	160
592	Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. 2001 , 28, 19-27	67
591	Distribution of HIV-1 plasma RNA viral load and CD4 + T-cell counts among HIV-infected Africans evaluated for antiretroviral therapy. 2001 , 28, 99-101	4
590	The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals. 2001 , 91, 1019-24	320
589	Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. 2001 , 26, 462-5	8

588	Comparison of Virologic, Immunologic, and Clinical Response to Five Different Initial Protease Inhibitor-Containing and Nevirapine-Containing Regimens. 2001 , 27, 350-364		9
587	Long-Term Follow-Up of Antiretroviral-Naive HIV-Positive Patients Treated With Nevirapine. 2001 , 26, 462-465		12
586	Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step. 2001 , 3, 93-99		18
585	Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. <i>Journal of General Internal Medicine</i> , 2001 , 16, 850-859	4	44
584	Evaluating HIV-infected patients with headache: who needs computed tomography?. 2001 , 41, 441-8		5
583	Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. 2001 , 2, 43-51		14
582	Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. 2001 , 7, 678-81		14
581	Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy. 2001 , 6, 212-8		8
580	Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. 2001 , 64, 199-206		4
579	The relation between beliefs about drug treatments for HIV and sexual risk behavior in gay and bisexual men. 2001 , 23, 304-12		44
578	Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. 2001 , 33, 700-5		138
577	Hospitalization Rates in an Urban Cohort After the Introduction of Highly Active Antiretroviral Therapy. 2001 , 27, 143-152		65
576	Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. 2001 , 27, 350-64		23
575	Cost-Effectiveness of the Mpowerment Project, a Community-Level Intervention for Young Gay Men. 2001 , 27, 482-491		11
574	Sequencing antiretroviral drugs. 2001 , 15, 547-51		11
573	A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. 2001 , 27, 116-23		7
572	Alternative strategies for anti-HIV treatment. 2001 , 15 Suppl 5, S161-9		3
571	Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. 2001 , 15, 1679-86		29

570	Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?. 2001 , 15 Suppl 2, S36-42	18
569	Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV. 2001 , 2, 31-7	17
568	Heterogeneity of patients' adherence profile to antiretroviral therapy in HIV-infected patients. 2001 , 28, 307-8	1
567	A Randomized, Open-Label, Comparative Trial of Zidovudine Plus Lamivudine Versus Zidovudine Plus Lamivudine Plus Didanosine in Antiretroviral-Naive HIV-1-Infected Thai Patients. 2001 , 27, 116-123	7
566	Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. 2001 , 28, 445-9	364
565	Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. 2001 , 27, 251-9	274
564	Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men. 2001 , 27, 482-91	28
563	Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice. 2001 , 2, 474-6	10
562	Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. 2001 , 2, 38-45	179
561	Eligibility policies for the state AIDS drug assistance programs. 2001 , 32, 81-104	3
560	Discontinuation of <i>Pneumocystis carinii</i> prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. 2001 , 33, 1901-9	15
559	Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. 2001 , 33, 865-72	164
558	Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. 2001 , 33, 1417-23	494
557	Determinants of antimicrobial prophylaxis use and treatment for wasting among patients with advanced human immunodeficiency virus disease in the United States, 1995-1998. 2001 , 32, 116-23	1
556	The AIDS drug assistance programs and coverage of HIV-related medications. 2001 , 35, 155-66	8
555	Satisfaction with innovative community and university health clinic programs for groups of traditionally underserved individuals with HIV/AIDS: empirical models. 2001 , 19, 77-102	3
554	Is the placebo powerless?. 2001 , 345, 1276-7; author reply 1278-9	32
553	Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. 2001 , 15, 193-9	69

552	Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study. 2001 , 15, 129-36	5
551	Alcohol use and HIV pharmacotherapy. 2002 , 18, 757-70	57
550	Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?. 2002 , 16, 527-35	47
549	AIDS-related systemic non-Hodgkin's lymphoma at a large community program. 2002 , 18, 237-42	28
548	Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. 2002 , 18, 89-94	38
547	Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. 2002 , 18, 419-26	20
546	Combination genetic therapy to inhibit HIV-1. 2002 , 5, 33-41	24
545	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. 2002 , 16, 1039-44	86
544	Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. 2002 , 16, 537-42	23
543	Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. 2002 , 29, 244-53	112
542	Antiretroviral Therapy in Resource-Limited Settings. 2002 , 322-344	
541	Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. 2002 , 31, 478-82	26
540	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). 2002 , 16, 369-79	154
539	Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome. 2002 , 34, 1129-36	24
538	Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. 2002 , 34, 239-47	30
537	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. 2002 , 99, 13747-52	176
536	Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. 2002 , 35, 1238-43	65
535	Adherence to HAART among patients with HIV: breakthroughs and barriers. 2002 , 14, 309-18	112

534	Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. 2002 , 30, 278-87	67
533	Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. 2002 , 31 Suppl 3, S112-7	91
532	Pharmacokinetic Variability Caused by Gender: Do Women Have Higher Indinavir Exposure Than Men?. 2002 , 29, 101-102	25
531	Predictive value of HIV-1 viral load on risk for opportunistic infection. 2002 , 30, 154-8	24
530	Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. 2002 , 31 Suppl 3, S98-102	68
529	Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. 2002 , 16, 21-9	124
528	The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. 2002 , 16, F33-40	56
527	A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. 2002 , 16, 579-88	136
526	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. 2002 , 16, 551-60	114
525	HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. 2002 , 16, 387-96	32
524	State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. 2002 , 40, 429-41	21
523	Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. 2002 , 40, 976-95	16
522	Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. 2002 , 16, 767-74	253
521	Gender difference in HIV RNA levels: a meta-analysis of published studies. 2002 , 31, 11-9	92
520	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. 2002 , 16, 53-61	80
519	Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. 2002 , 16, 1617-26	100
518	Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. 2002 , 99, 4250-1	7
517	Stem cell transplantation and gene therapy for HIV-related lymphomas. 2002 , 11, 765-75	7

516	Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. 2002 , 113, 91-8	123
515	RNA as a drug target. 2002 , 39, 73-119	16
514	HIV disease and advanced age: an increasing therapeutic challenge. 2002 , 19, 647-69	48
513	Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. 2002 , 360, 34-40	254
512	Current strategies in the treatment of HIV infection. 2002 , 48, A3-184	2
511	Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus. 2002 , 13, 60-5	12
510	Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. 2002 , 20 Suppl 4, A52-60	19
509	[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. 2002 , 20, 244-303	20
508	Nontuberculous mycobacteria in the HIV infected patient. 2002 , 23, 665-74	44
507	[Adherence to antiretroviral drug therapy. A systematic review]. 2002 , 119, 130-7	19
506	Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España. 2002 , 119, 721-724	2
505	Estudio de las variables asociadas a la aparición de éxito y fracaso en términos de carga viral en individuos con infección por el virus de la inmunodeficiencia humana. 2002 , 118, 689-693	
504	Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. 2002 , 35, 1173-81	59
503	The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. 2002 , 23, 198-220	74
502	Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. 2002 , 54, 1481-96	230
501	Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. 2002 , 55, 235-46	149
500	Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. 2002 , 68, 473-8	12
499	AIDS-related tumors: integrating antiviral and anticancer therapy. 2002 , 41, 299-315	26

498	A prospective study of predictors of adherence to combination antiretroviral medication. <i>Journal of General Internal Medicine</i> , 2002 , 17, 756-65	4	389
497	Paediatric antiretroviral therapy audit in South London. 2002 , 3, 44-8		3
496	Switch studies: a review. 2002 , 3, 146-55		38
495	Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm ³ : is there a benefit to treat with highly active antiretroviral therapy (HAART)?. 2004 , 19, 597-604		4
494	Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. 2003 , 80, 416-27		60
493	Modeling immune intervention strategies for HIV-1 infection of humans in the macaque model. 2003 , 3, 289-306		3
492	Informal HIV caregiving in a vulnerable population: toward a network resource framework. 2003 , 56, 1307-20		41
491	Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by <i>Phyllanthus amarus</i> . 2003 , 58, 175-86		74
490	Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2003 , 57, 600-7		7
489	Findings from the first national clinical audit of treatment for people with HIV. 2003 , 4, 11-7		26
488	Simplified Regimens for Treating HIV Infection and AIDS. 2003 , 15, 353-360		
487	Simplified regimens for treating HIV infection and AIDS. 2003 , 15, 305-12		5
486	Respuesta inmunológica, virológica y clínica en pacientes infectados por el VIH tras terapia antirretroviral de gran eficacia con nelfinavir: estudio sobre una cohorte prospectiva. 2003 , 21, 543-551		
485	[Once-a-day highly active antiretroviral therapy. Present or future?]. 2003 , 121, 304-9		1
484	Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. 2003 , 17, 155-68		54
483	Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective. 2003 , 63, 1325-37		11
482	Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. 2003 , 115, 632-41		87
481	Decline in the AIDS and death rates in the EuroSIDA study: an observational study. 2003 , 362, 22-9		1038

480	Treatment of antiretroviral-drug-resistant HIV-1 infection. 2003 , 362, 2002-11	165
479	An editorial for the HIV infected: immune regulation. The implications for treatment of HIV infection and the potential role of T cell suppressor pathways instead of apoptosis, anergy or direct CD4 T cell deletion in AIDS pathogenesis. 2003 , 60, 373-81	2
478	Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS. 2003 , 14, 37-45	39
477	Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort. 2003 , 27, 252-62	2
476	Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics. 2003 , 1, 75-81	4
475	Atazanavir: improving the HIV protease inhibitor class. 2003 , 1, 403-13	15
474	Factors affecting patient adherence to highly active antiretroviral therapy. 2003 , 37, 775-81	26
473	HIV-infected inpatients in the HAART era: how do hepatitis C virus coinfecting patients differ?. 2003 , 17, 13-6	8
472	New anti-HIV protease inhibitors provide more treatment options. 2003 , 17, 551-64	4
471	Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. 2003 , 19, 653-6	8
470	R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naïve patients treated mostly with a nelfinavir-containing regimen. 2003 , 47, 3623-6	7
469	HIV viral suppression in the era of antiretroviral therapy. 2003 , 79, 36-42	21
468	Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. 2003 , 37, 1112-8	366
467	Adherence is not a barrier to successful antiretroviral therapy in South Africa. 2003 , 17, 1369-75	209
466	Patterns of adherence to antiretroviral medications: the value of electronic monitoring. 2003 , 17, 1763-7	41
465	Trial and error. 2003 , 17, 619-623	6
464	Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. 2003 , 17, 801-7	20
463	Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy. 2003 , 33, 614-24	15

462	Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. 2003 , 33, 321-8	46
461	Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. 2003 , 17, 1933-9	5
460	Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. 2003 , 17, 2419-27	58
459	Differences in durability of treatment with initial PI-based regimens. 2003 , 4, 391-9	5
458	New antiretroviral drugs and approaches to HIV treatment. 2003 , 17 Suppl 4, S85-96	3
457	Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood stem cell-based gene therapy. 2003 , 17, 563-74	16
456	Virological rebound after suppression on highly active antiretroviral therapy. 2003 , 17, 1741-51	83
455	Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. 2003 , 4, 361-71	16
454	Adherence and potency with antiretroviral therapy: a combination for success. 2003 , 34 Suppl 2, S118-22	5
453	Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. 2003 , 34, 174-83	58
452	European guidelines for the clinical management and treatment of HIV-infected adults in Europe. 2003 , 17, S3-S26	33
451	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. 2003 , 17, 987-99	131
450	Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. 2003 , 32, 259-67	101
449	Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients. 2003 , 32, 494-8	6
448	The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. 2003 , 82, 77-81	22
447	Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. 2003 , 17, 2629-34	13
446	Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. 2003 , 25, 73-80	65
445	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. 2003 , 17, 1907-15	197

444	Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. 2003 , 32, 399-405	97
443	Doubts about DOT: antiretroviral therapy for resource-poor countries. 2003 , 17, 1383-7	40
442	Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. 2003 , 17, 2451-9	38
441	The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. 2003 , 17 Suppl 4, S51-60	34
440	Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution. 2003 , 33, 651-3	11
439	Perceived employment barriers and their relation to workforce-entry intent among people with HIV/AIDS. 2003 , 8, 181-94	46
438	Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. 2003 , 14, 201-5	4
437	Managing failure to antiretroviral drugs in HIV-1-infected patients. 2003 , 16, 9-18	2
436	Structured treatment interruptions in HIV infection: benefit or disappointment?. 2003 , 1, 129-39	9
435	Initiating HIV therapy. Timing is critical, controversial. 2004 , 115, 15-8, 21, 24-6	3
434	Natural history of patients with low-level HIV viremia on antiretroviral therapy. 2004 , 18, 436-42	7
433	Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. 2004 , 39, 248-55	67
432	The case for earlier treatment of HIV infection. 2004 , 39, 1699-704	56
431	Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. 2004 , 39, 717-24	50
430	Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study. 2004 , 54, 921-31	19
429	Pharmacologic perspectives for once-daily antiretroviral therapy. 2004 , 38, 1924-34	14
428	A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. 2004 , 5, 91-8	7
427	Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. 2004 , 36, 967-71	33

426	Quality Care for People with HIV/AIDS: patients' perspectives. 2004 , 5, 406-15	18
425	Safety/Tolerability and Efficacy of Abacavir-Containing Combination Therapy in HIV-1-Infected Adults in a Clinical Practice Setting: Results of ZORRO. 2004 , 12, 15-25	1
424	Determinants of sustained virological suppression in indigent, HIV-infected patients: is single protease inhibitor-based antiretroviral therapy truly highly active?. 2004 , 5, 117-24	5
423	Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. 2004 , 38 Suppl 5, S409-13	73
422	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. 2004 , 18, 2261-7	37
421	Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. 2004 , 78, 10133-48	113
420	Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. 2004 , 9, 902-13	113
419	Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. 2004 , 20, 1166-72	3
418	Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. 2004 , 20, 1053-6	157
417	Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. 2004 , 16 Suppl 1, S71-96	42
416	Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. 2004 , 39, 609-29	141
415	Oral contraception does not alter single dose saquinavir pharmacokinetics in women. 2004 , 57, 244-52	24
414	Determinants of long-term highly active antiretroviral treatment efficacy. 2004 , 5, 40-9	3
413	Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. 2004 , 5, 307-13	15
412	Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy. 2004 , 5, 364-70	4
411	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. 2004 , 5, 437-47	46
410	Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. 2004 , 13, 587-99	60
409	Adherence to antiretroviral therapy: an update of current concepts. 2004 , 1, 172-80	17

408	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. 2004 , 72, 181-6	7
407	HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count. 2004 , 74, 8-15	8
406	Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. 2004 , 78, 1718-29	157
405	Incorporating durability information in the comparison of proportions of patients with HIV suppression. 2004 , 14, 741-55	
404	Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. 2004 , 305, 528-32	267
403	[Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen]. 2004 , 22, 106-12	6
402	Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). 2004 , 22, 564-642	1
401	[Evaluation of drug addicts with associated pathology. Clinical and therapeutic aspects of the integral attention]. 2004 , 122, 624-35	1
400	Sex differences in pharmacokinetics and pharmacodynamics. 2004 , 44, 499-523	363
399	Predictors of virologic success in patients completing a structured antiretroviral adherence program. 2004 , 15, 60-7	7
398	[Duration of antiretroviral combinations]. 2004 , 122, 696-7	
397	Characterization of human immunodeficiency virus type-1 from HIV-1 seropositive cases with undetectable viremia. 2004 , 30, 224-8	4
396	[Identification of factors influencing the response of antiretroviral treatment]. 2004 , 34, 37-41	
395	HIV infection and advanced age emerging epidemiological, clinical, and management issues. 2004 , 3, 31-54	87
394	Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. 2004 , 23, 923-30	34
393	Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. 2004 , 23, 713-8	38
392	Antiretroviral therapy in the private sector of resource-limited settings. 2004 , 18, 581-2	1
391	Improving on success: what treating the urban poor in America can teach us about improving antiretroviral programmes in Africa. 2004 , 18 Suppl 3, S39-43	5

390	Effect of persistent moderate viremia on disease progression during HIV therapy. 2004 , 37, 1147-54	68
389	The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. 2004 , 18, 1895-904	16
388	Directly observed therapy for HIV antiretroviral therapy in an urban US setting. 2004 , 36, 642-5	26
387	Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. 2004 , 18, 2029-38	145
386	Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients. 2004 , 5, 65-73	4
385	The antiretroviral-experienced patient. 2004 , 328, 10-6	1
384	Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. 2005 , 19, 815-22	37
383	Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. 2005 , 38, 560-5	130
382	Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. 2005 , 40, 301-6	42
381	Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. 2005 , 19, 1081-9	97
380	Hospital and outpatient health services utilization among HIV-infected children in care 2000-2001. 2005 , 43, III31-9	5
379	Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. 2005 , 43, III15-22	8
378	Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study. 2005 , 6, 320-8	18
377	Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. 2005 , 38, 578-83	35
376	HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. 2005 , 40, 34-40	62
375	Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. 2005 , 40, 324-8	44
374	The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. 2005 , 7, 302-9	97
373	Modeling and simulation of adherence: approaches and applications in therapeutics. 2005 , 7, E390-407	30

372	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). 2005 , 6 Suppl 2, 1-61	120
371	Medication practice and feminist thought: a theoretical and ethical response to adherence in HIV/AIDS. 2005 , 19, 362-78	18
370	Approaches to antiretroviral therapy in China. 2005 , 15, 895-902	1
369	Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir. 2005 , 76, 447-51	5
368	The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?. 2005 , 2, 177-83	33
367	Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs. 2005 , 2, 61-7	2
366	Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy. 2005 , 50, 230-4	55
365	Managing patients with sexual transmission of drug-resistant HIV. 2005 , 2, 135-42	6
364	Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. 2005 , 17, 493-504	102
363	Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1. 2005 , 79, 5907-13	13
362	Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. 2005 , 352, 570-85	465
361	Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. 2005 , 12, 1157-67	13
360	Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. 2005 , 4, 66-72	18
359	Impact of an Adherence Program on the Health and Outlook of HIV-Infected Patients Failing Antiretroviral Therapy. 2005 , 4, 59-65	5
358	Adherence to Antiretroviral Therapy: The Emerging Role of HIV Pharmacotherapy Specialists. 2005 , 18, 247-257	6
357	Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. 2005 , 161, 881-90	27
356	Antiretroviral treatment in correctional facilities. 2005 , 6, 25-37	27
355	Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. 2005 , 19, 357-70	68

354	Antiretroviral therapies for treatment-experienced patients: current status and research challenges. 2005 , 19, 747-56	37
353	Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. 2005 , 19 Suppl 3, S190-8	13
352	Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. 2005 , 21, 398-406	9
351	Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic. 2005 , 19, 785-93	9
350	Review of atazanavir: a novel HIV protease inhibitor. 2005 , 6, 1565-72	21
349	Enfuvirtide: the first HIV fusion inhibitor. 2005 , 6, 453-64	32
348	Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. 2005 , 17, 902-7	118
347	Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. 2005 , 17, 1022-9	29
346	Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in So Paulo, Brazil. 2005 , 32, 336-7	4
345	Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. 2005 , 33, 206-16	41
344	Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. 2005 , 27, 199-209	86
343	Estimating the proportion of patients infected with HIV who will die of comorbid diseases. 2005 , 118, 890-8	110
342	The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. 2005 , 14, 681-93	41
341	Economic models of antiretroviral therapy: searching for the optimal strategy. 2006 , 24, 631-42	11
340	Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. 2006 , 2, 273-83	39
339	Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations. 2006 , 18, 968-76	27
338	Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. 2006 , 6, 496-507	20
337	Ancillary services for individuals living with HIV/AIDS. 2006 , 41, 383-93, vi	3

336	Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. 2006 , 66, 769-89	256
335	Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. 2006 , 118, e1745-57	223
334	Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. 2006 , 16, 104-12	23
333	High incidence of adverse reactions to initial antiretroviral therapy in Brazil. 2006 , 39, 495-505	20
332	Overview of HIV drug resistance and its implications for China. 2006 , 119, 1999-2004	10
331	Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users. 2006 , 41, 486-92	75
330	Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. 2006 , 20, 397-404	6
329	The independent effect of drug resistance on T cell activation in HIV infection. 2006 , 20, 691-9	31
328	Evaluation and management of early virological failure. 2006 , 1, 409-16	
327	Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. 2006 , 41, 632-41	59
326	Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption. 2006 , 4, 7	5
325	CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system. 2006 , 7, 504-13	6
324	Adherence to treatment in Swedish HIV-infected patients. 2006 , 31, 605-16	38
323	Caring for adolescents with HIV. 2006 , 3, 74-8	25
322	Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. 2006 , 26, 1679-86	9
321	Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors. 2006 , 1, 82-95	18
320	Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. 2006 , 43, 411-7	237
319	Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. 2006 , 43 Suppl 1, S123-6	124

318	Five year outcomes of a cohort of HIV-infected injection drug users in a primary care practice. 2006 , 25, 33-8	7
317	Cost-effectiveness of HIV treatment in resource-poor settings—the case of Cte d'Ivoire. 2006 , 355, 1141-53	218
316	HIV infection in older patients in the HAART era. 2006 , 57, 4-7	105
315	Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. 2006 , 163, 412-20	144
314	Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. 2006 , 42, 136-44	28
313	Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. 2006 , 42, 252-9	85
312	A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. 2006 , 42, 1619-27	79
311	The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. 2006 , 43 Suppl 4, S178-83	41
310	Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women. 2006 , 22, 222-31	9
309	Type of substance use and access to HIV-related health care. 2006 , 20, 399-407	42
308	Communication of HIV viral load to guide sexual risk decisions with serodiscordant partners among San Francisco men who have sex with men. 2006 , 18, 983-9	12
307	Religious beliefs, practices and treatment adherence among individuals with HIV in the southern United States. 2006 , 20, 97-111	68
306	Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. 2006 , 22, 132-8	13
305	Community outreach with weekly delivery of anti-retroviral drugs compared to cognitive-behavioural health care team-based approach to improve adherence among indigent women newly starting HAART. 2006 , 18, 332-8	18
304	Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. 2006 , 22, 213-21	32
303	Retention in care: a challenge to survival with HIV infection. 2007 , 44, 1493-9	461
302	Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. 2007 , 21, 920-9	11
301	Predictors of antiretroviral treatment failure in an urban HIV clinic. 2007 , 44, 30-7	70

300	Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. 2007 , 44, 268-77	35
299	Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. 2007 , 19, 138-45	45
298	Monotherapy with lopinavir/ritonavir. 2007 , 16, 735-41	6
297	Validity of a stage of change instrument in assessing medication adherence in indigent patients with HIV infection. 2007 , 41, 208-14	14
296	Tipranavir: a new option for the treatment of drug-resistant HIV infection. 2007 , 45, 761-9	25
295	Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. 2007 , 44, 1235-44	70
294	Important considerations regarding antiretroviral therapy in HIV-positive women. 2007 , 1, 203-213	1
293	Barriers to highly active antiretroviral therapy adherence in sub-Saharan Africa. 2007 , 1, 331-339	4
292	Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. 2007 , 45, 401-10	20
291	Antiretroviral therapy adherence in resource-limited and resource-rich settings: current status of knowledge and research priorities. 2007 , 4, 775-786	3
290	Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. 2007 , 8, 9-18	8
289	Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. 2007 , 46 Suppl 2, S64-71	69
288	Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. 2007 , 38, 313-20	30
287	Rate and predictors of optimal virologic response to antiretroviral therapy in Colombia. 2007 , 11, 531-5	9
286	Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore. 2007 , 33, 71-80	10
285	Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women. 2007 , 89, 277-90	21
284	Investigation of novel lipid-functionalized PNA monomers as potential HIV-1 non-nucleoside reverse transcriptase and/or integrase inhibitors. 2007 , 26, 1063-6	2
283	Antiretroviral pharmacokinetic profile: a review of sex differences. 2007 , 4, 106-19	84

282	[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)]. 2007 , 25, 32-53		37
281	[Adverse side effects of antiretroviral therapy: relationship between patients' perception and adherence]. 2007 , 129, 127-33		8
280	Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil. 2007 , 40, 551-5		11
279	Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil. 2007 , 40, 963-9		1
278	One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. 2007 , 261, 268-75		112
277	Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. 2007 , 8, 406-10		41
276	The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. 2007 , 8, 439-50		16
275	Psychosocial predictors of medication adherence among persons living with HIV. 2007 , 14, 141-50		49
274	Adherence to therapy: Challenges in HCV-infected patients. 2007 , 6, 160-168		1
273	Should antiretroviral therapy be started earlier?. 2007 , 4, 53-9		4
272	Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. <i>Journal of General Internal Medicine</i> , 2007 , 22, 1325-9	4	68
271	Management of HIV infection in patients with substance use problems. 2008 , 10, 432-8		13
270	HIV/AIDS health service utilization by people who have been homeless. 2008 , 12, 815-21		6
269	[Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)]. 2008 , 26, 127-34		17
268	[First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated with therapy changes]. 2008 , 26, 416-22		2
267	Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions. 2008 , 35, 294-303		36
266	[New therapeutic options in protracted HIV-infected patients with virological failure]. 2008 , 130, 66-70		1
265	[Efficacy of atazanavir in rescue therapy]. 2008 , 26 Suppl 17, 22-7		4

264	Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. 2008 , 20, 311-7	72
263	Impact of depression on HIV outcomes in the HAART era. 2008 , 62, 246-55	96
262	The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. 2008 , 28, 359-76	23
261	Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. 2008 , 9, 91-102	10
260	Second generation HIV protease inhibitors against resistant virus. 2008 , 3, 775-86	6
259	Running with scissors: using antiretroviral therapy without monitoring viral load. 2008 , 46, 1598-600	34
258	Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. 2009 , 63, 189-96	5
257	Short-term discontinuation of HAART regimens more common in vulnerable patient populations. 2008 , 24, 1347-55	37
256	Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. 2008 , 24, 685-94	23
255	Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission. 2008 , 24, 1429-33	
254	Self-reported reasons among HIV-infected patients for missing clinic appointments. 2008 , 19, 125-6	18
253	Virologic success in an urban HIV clinic: outcome at 12 months in patients who were HAART naïve. 2008 , 9, 186-91	3
252	Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. 2008 , 22, 2331-9	56
251	Psychiatric Barriers and the International AIDS Epidemic. 2008 , 271-277	
250	Cost-effectiveness of HIV screening in patients older than 55 years of age. <i>Annals of Internal Medicine</i> , 2008 , 148, 889-903	8 50
249	Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the Division of Infectious Diseases, UNIFESP. 2009 , 81, 571-87	8
248	Gender disparities in HIV health care utilization among the severely disadvantaged: can we determine the reasons?. 2009 , 23, 775-83	54
247	The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study. 2009 , 21, 520-8	37

246	Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. 2009 , 50, 276-82		57
245	Predictors of retention in HIV care among a national cohort of US veterans. 2009 , 10, 299-305		99
244	Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients?. 2009 , 21, 842-50		14
243	Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. 2009 , 49, 1582-90		51
242	Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy. 2009 , 38, 197-207		30
241	Vulnerabilities and caregiving in an ethnically diverse HIV-infected population. 2009 , 13, 337-47		4
240	Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. <i>Journal of General Internal Medicine</i> , 2009 , 24, 1065-72	4	69
239	Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. 2009 , 18, 848-57		17
238	Host sequence motifs shared by HIV predict response to antiretroviral therapy. 2009 , 2, 47		10
237	A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India. 2009 , 34, 33-40		10
236	The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly. 2009 , 276, 6110-7		24
235	Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability. 2009 , 44, 124-132		15
234	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. 2009 , 52, 7473-87		17
233	HIV and tuberculosis in Durban, South Africa: adherence to two medication regimens. 2009 , 21, 1106-13		10
232	Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. 2009 , 49, 651-81		281
231	Chapter 13:From Natural Product to Clinical Trials: Bevirimat, a Plant-Derived Anti-AIDS Drug. 2009 , 374-391		5
230	Epidemiology of treatment failure: a focus on recent trends. 2009 , 4, 467-73		11
229	Mortality among injection drug users in Chennai, India (2005-2008). 2009 , 23, 997-1004		31

228	Racial disparities in HIV virologic failure: do missed visits matter?. 2009 , 50, 100-8	139
227	Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. 2010 , 5, 70-7	93
226	Rates of initial virological suppression and subsequent virological failure after initiating highly active antiretroviral therapy: the impact of aboriginal ethnicity and injection drug use. 2010 , 8, 649-58	11
225	Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings. 2010 , 24, 1887-95	9
224	Using mobile phones to improve clinic attendance amongst an antiretroviral treatment cohort in rural Uganda: a cross-sectional and prospective study. 2010 , 14, 1347-52	77
223	Entry inhibitors in the treatment of HIV-1 infection. 2010 , 85, 91-100	167
222	The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. 2010 , 13, 49	56
221	Situational analysis of varying models of adherence support and loss to follow up rates; findings from 27 treatment facilities in eight resource limited countries. 2010 , 15 Suppl 1, 76-81	25
220	Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. 2010 , 53, 648-55	194
219	Patients with Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. 2010 , 353-370	2
218	Clinic Attendance for Medication Refills and Medication Adherence amongst an Antiretroviral Treatment Cohort in Uganda: A Prospective Study. 2010 , 2010, 872396	27
217	Adherence to antiretroviral therapy in Nigeria: an overview of research studies and implications for policy and practice. 2010 , 2, 69-76	13
216	High adherence and concordance within a clinical trial of antihypertensives. 2010 , 6, 243-51	24
215	Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults. 2010 , 9, 273-7	3
214	Role of the CD4 count in HIV management. 2010 , 4, 27-39	16
213	Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. 2010 , 50, 574-84	15
212	Predicting virologic failure in an HIV clinic. 2010 , 50, 779-86	55
211	How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia. 2010 , 22, 1323-31	12

210	From access to engagement: measuring retention in outpatient HIV clinical care. 2010 , 24, 607-13		198
209	HIV-infected patients and treatment outcomes: an equivalence study of community-located, primary care-based HIV treatment vs. hospital-based specialty care in the Bronx, New York. 2010 , 22, 1522-9		23
208	Predictors of success with highly active antiretroviral therapy in an antiretroviral-naïve urban population. 2010 , 26, 133-8		31
207	Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico. 2010 , 26, 373-8		11
206	Self-Reported Satisfaction with HIV Services Including the AIDS Drug Assistance Program. 2011 , 10, 139-160		
205	NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs. 2011 , 37, 283-93		5
204	Crossing the divide: transition care services for young people with HIV-their views. 2011 , 25, 465-73		39
203	Symptoms experienced by HIV-infected Individuals on antiretroviral therapy in KwaZulu-Natal, South Africa. 2011 , 24, 1-9		20
202	Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. 2011 , 88, 948-52		54
201	Elevated CD8 counts during HAART are associated with HIV virologic treatment failure. 2011 , 57, 396-403		17
200	Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. <i>PLoS ONE</i> , 2011 , 6, e18453	3.7	78
199	Nausea and vomiting in HIV/AIDS. 2011 , 34, 15-24		6
198	Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy. 2011 , 25, 951-6		38
197	Lopinavir: the old champion. 2011 , 6, 561-570		1
196	Psychometric properties of a Symptom Management Self-Efficacy Scale for women living with HIV/AIDS. 2011 , 41, 549-57		11
195	Characteristics and Outcomes of Chronic Kidney Disease Patients Who Default on Appointments at a Low Clearance Clinic. 2011 , 13, 33-38		3
194	Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. <i>AIDS Research and Therapy</i> , 2011 , 8, 42	3	33
193	Synthesis of a labeled inhibitor of HIV-1 attachment: 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridinyl-3-yl)-[U-14C]ethane-1,2-dione, BMS-488043-14C. 2011 , 54, 289-291		0

192	Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. 2011 , 46, 979-92	39
191	The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. 2011 , 11, 124-33	17
190	Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia. 2011 , 85, 782-9	53
189	Early linkage and retention in care: findings from the outreach, linkage, and retention in care initiative among young men of color who have sex with men. 2011 , 25 Suppl 1, S31-8	56
188	Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. 2011 , 53, 600-4	43
187	Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. 2011 , 53, 725-31	63
186	Antiretroviral therapy: now "it just works". 2011 , 53, 605-8	2
185	Optimal HAART adherence over time and time interval between successive visits: their association and determinants. 2011 , 23, 1417-24	8
184	Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa. 2012 , 2012, 574656	94
183	Resistance evolution in HIV - modeling when to intervene. 2012 , 2012, 4053-4058	
182	Impact of transitioning from HIV clinical trials to routine medical care on clinical outcomes and patient perceptions. 2012 , 24, 769-77	3
181	Tuberculosis and lactic acidosis as causes of death in adult patients from a regional hospital in Johannesburg. 2012 , 4,	1
180	Association between missed early visits and mortality among patients of china national free antiretroviral treatment cohort. 2012 , 60, 59-67	29
179	Establishment, retention, and loss to follow-up in outpatient HIV care. 2012 , 60, 249-59	126
178	Comparing different measures of retention in outpatient HIV care. 2012 , 26, 1131-9	97
177	Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico. 2012 , 59, 155-60	10
176	Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. 2012 , 59, 393-9	49
175	Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. 2012 , 26, 1403-13	27

174	Determinants of HIV drug resistance and public health implications in low- and middle-income countries. <i>Antiviral Therapy</i> , 2012 , 17, 941-53	1.6	25
173	Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. <i>Annals of Internal Medicine</i> , 2012 , 156, 817-33, W-284, W-285, W-286, W-287, W-288, W-289,	8	458
172	Systematic identification of synergistic drug pairs targeting HIV. 2012 , 30, 1125-30		84
171	Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. 2012 , 124, 108-12		26
170	Psychiatric barriers and the international AIDS epidemic. 2012 , 257-266		
169	A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. <i>PLoS ONE</i> , 2012 , 7, e44833	3.7	33
168	Treating women with HIV: is it different than treating men?. 2012 , 9, 171-8		25
167	The enhancement of RNAi against HIV in vitro and in vivo using H-2K(k) protein as a sorting method. 2012 , 182, 9-17		7
166	Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients. 2012 , 13, 345-51		
165	Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. 2012 , 12, 7		46
164	Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. 2012 , 15, 10		68
163	Non-natural peptide triazole antagonists of HIV-1 envelope gp120. 2013 , 8, 322-8		9
162	HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. 2013 , 81, 271-90		13
161	Identification of the potential regions of Epap-1 that interacts with V3 loop of HIV-1 gp120. 2013 , 1834, 780-90		1
160	Sex differences in prophylaxis and therapeutic treatments for viral diseases. 2012 , 499-522		14
159	Is it time for treatment as prevention among people who inject drugs?. 2013 , 63, 545-7		9
158	Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. 2013 , 27, 2559-66		82
157	Initial linkage and subsequent retention in HIV care for a newly diagnosed HIV-infected cohort in Denver, Colorado. 2013 , 12, 384-90		12

156	Conformity of pediatric/adolescent HIV clinics to the patient-centered medical home care model. 2013 , 27, 272-9		12
155	The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression. 2013 , 27, 459-66		22
154	Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic. 2013 , 27, 205-7		1
153	Impact of pre-therapy viral load on virological response to modern first-line HAART. <i>Antiviral Therapy</i> , 2013 , 18, 867-76	1.6	31
152	Nonadherence to clinic appointments among HIV-infected children in an ambulatory care program in western Kenya. 2013 , 63, e49-55		15
151	Caring for women living with HIV: gaps in the evidence. 2013 , 16, 18509		44
150	Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. <i>PLoS ONE</i> , 2013 , 8, e56307	3.7	29
149	The effects of a problem solving-based intervention on depressive symptoms and HIV medication adherence are independent. <i>PLoS ONE</i> , 2014 , 9, e84952	3.7	7
148	African American race and HIV virological suppression: beyond disparities in clinic attendance. 2014 , 179, 1484-92		25
147	The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans. 2014 , 30, 233-40		17
146	Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. 2014 , 59, 725-34		117
145	Household food insecurity associated with antiretroviral therapy adherence among HIV-infected patients in Windhoek, Namibia. 2014 , 67, e115-22		32
144	Impact of non-HIV related comorbidities on retention in HIV medical care: does retention improve over time?. 2014 , 18, 617-24		13
143	Deep sequencing of HIV: clinical and research applications. 2014 , 15, 295-325		25
142	Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. 2014 , 58, e1-34		242
141	Effects of an intervention addressing information, motivation, and behavioral skills on HIV care adherence in a southern clinic cohort. 2014 , 26, 674-83		13
140	Combinatorial therapy discovery using mixed integer linear programming. 2014 , 30, 1456-63		50
139	Outcomes of HIV-infected patients receiving care at multiple clinics. 2014 , 18, 1511-22		11

138	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. 2014 , 80, 112-21		24
137	Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care?. 2014 , 33, 924-30		32
136	Psychometric Developments in Psychosocial Assessment in Behavioral Medicine Settings. 2014 , 353-405		1
135	Retention in care is more strongly associated with viral suppression in HIV-infected patients with lower versus higher CD4 counts. 2014 , 65, 333-9		51
134	Correlates of mobile phone use in HIV care: Results from a cross-sectional study in South Africa. 2015 , 2, 512-6		10
133	Evaluating patterns in retention, continuation, gaps, and re-engagement in HIV care in a Medicaid-insured population, 2006-2012, United States. 2015 , 27, 1387-95		12
132	IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. 2015 , 14 Suppl 1, S3-S34		68
131	A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999-2008. 2015 , 69, 481-6		31
130	The effects of a pharmacist-delivered patient education programme on retention in human immunodeficiency virus care: a pilot study. 2015 , 6, 83-89		5
129	Comparative value of four measures of retention in expert care in predicting clinical outcomes and health care utilization in HIV patients. <i>PLoS ONE</i> , 2015 , 10, e0120953	3-7	11
128	A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients. <i>PLoS ONE</i> , 2015 , 10, e0130090	3-7	5
127	Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project. 2015 , 29, 2223-34		12
126	Moving toward a novel and comprehensive behavioral composite of engagement in HIV care. 2015 , 27, 660-4		8
125	Barriers and facilitators to patient retention in HIV care. 2015 , 15, 246		118
124	Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, Nigeria. 2014 , 48, 194-203		10
123	Efficacy of generic highly active antiretroviral therapy in HIV-1 infected individuals in Nigeria. 2015 , 36, 464-77		4
122	Recall of Nadir CD4 Cell Count and Most Recent HIV Viral Load Among HIV-Infected, Socially Marginalized Adults. 2015 , 19, 2108-16		10
121	Predicting Non-Adherence with Outpatient Colonoscopy Using a Novel Electronic Tool that Measures Prior Non-Adherence. <i>Journal of General Internal Medicine</i> , 2015 , 30, 724-31	4	21

120	Impact of age on retention in care and viral suppression. 2015 , 68, 413-9	69
119	Retention in care and medication adherence: current challenges to antiretroviral therapy success. 2015 , 75, 445-54	71
118	Gold nanoparticles to improve HIV drug delivery. 2015 , 7, 1097-107	47
117	Magnitude of adverse drug reaction and associated factors among HIV-infected adults on antiretroviral therapy in Hiwot Fana specialized university hospital, eastern Ethiopia. 2016 , 24, 255	12
116	Predictors of Poor Retention in Care of HIV-infected Patients Receiving Antiretroviral Therapy in Korea: Five-Year Hospital-based Retrospective Cohort Study. 2016 , 31, 376-81	5
115	Factors associated with 10 years of continuous viral load suppression on HAART. 2016 , 16, 351	8
114	Sex and gender differences in HIV-1 infection. 2016 , 130, 1435-51	42
113	Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy. 2016 , 95, e4570	5
112	Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC. 2016 , 28, 1355-64	37
111	Antiretroviral Refill Adherence Correlates with, But Poorly Predicts Retention in HIV Care. 2016 , 20, 1060-7	9
110	Linkage to and retention in care following healthcare transition from pediatric to adult HIV care. 2016 , 28, 561-5	56
109	The Impact of Youth-Friendly Structures of Care on Retention Among HIV-Infected Youth. 2016 , 30, 170-7	37
108	Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study. 2017 , 28, 491-498	2
107	Residential Eviction and Risk of Detectable Plasma HIV-1 RNA Viral Load Among HIV-Positive People Who Use Drugs. 2017 , 21, 678-687	28
106	Self-disclosure of HIV status, disclosure counseling, and retention in HIV care in Cameroon. 2017 , 29, 838-845	7
105	HIV-infected individuals who use alcohol and other drugs, and virologic suppression. 2017 , 29, 1129-1136	29
104	High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study. 2017 , 96, e6282	15
103	High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center. 2017 , 66, 1402-1412	33

102	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. 2017 , 4, ofx024		20
101	The Role of Caveolin 1 in HIV Infection and Pathogenesis. 2017 , 9,		15
100	Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. <i>PLoS ONE</i> , 2017 , 12, e0180140	3.7	2
99	Social and structural factors associated with greater time with a plasma HIV-1 RNA viral load above log ₁₀ (1500) copies/ml among illicit drug users. 2018 , 32, 1059-1067		3
98	Travel Time to Clinic but not Neighborhood Crime Rate is Associated with Retention in Care Among HIV-Positive Patients. 2018 , 22, 3003-3008		15
97	Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial. 2018 , 69, 48-54		8
96	Psychiatric Illness, Substance Use, and Viral Suppression Among HIV-Positive Men of Color Who Have Sex with Men in Los Angeles. 2018 , 22, 3117-3129		18
95	Beyond binary retention in HIV care: predictors of the dynamic processes of patient engagement, disengagement, and re-entry into care in a US clinical cohort. 2018 , 32, 2217-2225		23
94	The Association of Trauma with the Physical, Behavioral, and Social Health of Women Living with HIV: Pathways to Guide Trauma-informed Health Care Interventions. 2019 , 29, 376-384		16
93	Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. 2019 , 6, ofz426		3
92	Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. <i>Antiviral Therapy</i> , 2019 , 24, 321-331	1.6	3
91	Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. 2021 , 73, e3572-e3605		30
90	Effect of mobile text messages on antiretroviral medication adherence and patient retention in early HIV care: an open-label, randomized, single center study in south Florida. <i>AIDS Research and Therapy</i> , 2020 , 17, 16	3	3
89	Non-disclosure of HIV serostatus to sexual partners: Prevalence, risk factors and clinical impact in patients with HIV. 2021 , 22, 194-200		0
88	Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention. 2021 , 25, 354-359		38
87	Nanotechnology for virus treatment. 2021 , 36, 101031		25
86	Opioid use disorder and HIV. 2021 , 51-75		
85	A novel association of efavirenz induced severe cutaneous adverse reactions with HLA-DRB1*03:01: A case-control study from North-East India. 2021 , 34, e14760		1

84	Erratum to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. 2021 ,	1
83	First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklo Hospital, Bangkok, Thailand: 20 Years Experience. 2021 , 13, 261-269	0
82	A qualitative analysis of factors influencing antiretroviral adherence among persons living with HIV in Ghana.	0
81	Low level of tuberculosis preventive therapy incompleteness among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review. 2021 , 25, 100269	1
80	Nanomedicine as a promising strategy for the theranostics of infectious diseases. 2021 , 9, 7878-7908	3
79	Overcoming Challenges to Successful Treatment Outcomes in Minority Patients with HIV/AIDS. 2009 , 53-67	1
78	The Changing Face of HIV-Associated Cognitive and Neuropsychiatric Disturbance. 2009 , 133-186	1
77	Introduction to entry inhibitors in the management of HIV infection. 2007 , 1-15	1
76	Cytomegalovirus Infections of the Retina. 2006 , 1605-1623	2
75	Gastrointestinal and Hepatobiliary Manifestations of Human Immunodeficiency Virus Infection. 2010 , 1737-1744	1
74	Alcohol and HIV Interactions in the Natural History and Treatment of HIV/AIDS. 2005 , 799-818	1
73	Functionalized gold nanoparticles: promising and efficient diagnostic and therapeutic tools for HIV/AIDS. 2020 , 11, 1252-1266	19
72	Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. 2001 , 15, 1181-3	704
71	Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. 2001 , 15, 1183-4	10
70	Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of the experience of five physicians. 2003 , 17, 938-40	16
69	Relationship between antiretroviral drug plasma concentrations and viral load in children. 2003 , 32, 112-5	4
68	Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels. 2000 , 38, 309-12	8
67	Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study. 2014 , 4, 59-69	3

66	Benchmarks for antiretroviral therapy. 2000 , 105, 709-10		7
65	Hematologic Aspects of HIV/AIDS. 2001 , 463-78		25
64	Impact of sex and gender on COVID-19 outcomes in Europe. 2020 , 11, 29		496
63	Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors. 2013 , 19, 483-92		8
62	Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. 2008 , 9, 73-82		9
61	Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. <i>PLoS ONE</i> , 2013 , 8, e54665	3.7	29
60	Treatment outcomes in undocumented Hispanic immigrants with HIV infection. <i>PLoS ONE</i> , 2013 , 8, e60037	3.7	44
59	Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in the D'Arville national antiretroviral therapy program. <i>PLoS ONE</i> , 2014 , 9, e98183	3.7	19
58	A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. <i>PLoS ONE</i> , 2014 , 9, e105853	3.7	9
57	Comparison of Clinical Outcomes of Persons Living With HIV by Enrollment Status in Washington, DC: Evaluation of a Large Longitudinal HIV Cohort Study. <i>JMIR Public Health and Surveillance</i> , 2020 , 6, e16061	11.4	2
56	Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e190	7.6	16
55	HIV and older adults: clinical outcomes in the era of HAART. <i>Journal of Gerontological Nursing</i> , 2004 , 30, 16-24; quiz 55-6	1.2	7
54	Study of adverse drug reactions to antiretroviral therapy in a tertiary care hospital, Tirupati. <i>Perspectives in Clinical Research</i> , 2020 , 11, 158-163	1.4	2
53	Long-term outcomes of antiretroviral therapy in an adult HIV program: a 10-year retrospective cohort study in Kano, Nigeria. <i>Annals of Saudi Medicine</i> , 2015 , 35, 303-11	1.6	5
52	Gastrointestinal Parasitic Infections and Immunological Status of HIV/AIDS Coinfected Individuals in Nigeria. <i>Annals of Global Health</i> , 2019 , 85,	3.3	8
51	Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?. <i>Archives of Pathology and Laboratory Medicine</i> , 2003 , 127, 102-5	5	12
50	Effect of disclosure of HIV status on patient representation and adherence to clinic visits in eastern Uganda: A propensity-score matched analysis. <i>PLoS ONE</i> , 2021 , 16, e0258745	3.7	0
49	HIV Infection in Women. 2001 , 185-202		0

- 48 Antiretroviral Therapy. **2001**, 203-228
- 47 A perspective of the history of HAART. **2004**, 25-40
- 46 Causes of HIV treatment failure. **2004**, 159-194 0
- 45 The Role of Antiretroviral Therapy in Asia. **2004**, 407-419
- 44 HIV/AIDS Care: The Minimum Package and Scaling Up. **2008**, 71-84
- 43 Antiretroviral Therapy and Communities of Color. **2009**, 33-51
- 42 In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1. *Open Medical Informatics Journal*, **2010**, 4, 225-32 1
- 41 Inhibitors of the Human Immunodeficiency Virus Protease. 113-135
- 40 Women and Neuro-AIDS Conditions in the Era of HAART. 443-454
- 39 Effect of combinational non protease inhibitor ART treatment on CD4+ T lymphocyte count in AIDS patients: a study from East India. **2014**, 4, 17-20
- 38 Gastrointestinal, Hepatobiliary, and Pancreatic Manifestations of Human Immunodeficiency Virus Infection. **2015**, 1567-1573 1
- 37 EVALUATION OF THE ADVERSE REACTIONS OF ANTIRETROVIRAL DRUG REGIMENS IN A TERTIARY CARE HOSPITAL IN KOLKATA: A PROSPECTIVE OBSERVATIONAL STUDY. *Journal of Evidence Based Medicine and Healthcare*, **2016**, 3, 4278-4285 0
- 36 Human Leukocyte Antigens Class II Alleles Affecting the Response to 5 Year Antiretroviral Therapy in A Latvian Cohort. *Proceedings of the Latvian Academy of Sciences*, **2019**, 73, 84-88 0.3
- 35 Comparison of Clinical Outcomes of Persons Living With HIV by Enrollment Status in Washington, DC: Evaluation of a Large Longitudinal HIV Cohort Study (Preprint).
- 34 Women of Color and HIV. **2021**, 91-110
- 33 Therapeutic Drug Monitoring in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. **2008**, 201-210
- 32 Adverse effects of antiretroviral therapy for HIV infection. *Cmaj*, **2004**, 170, 229-38 3.5 101
- 31 Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. *Journal of General Internal Medicine*, **2001**, 16, 850-9 4 17

30	Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. <i>Public Health Reports</i> , 2002 , 117 Suppl 1, S60-6	2.5	8
29	Utilization of health care resources by HIV-infected white, African-American, and Hispanic men in the era before highly active antiretroviral therapy. <i>Journal of the National Medical Association</i> , 2003 , 95, 853-61	2.3	11
28	Improving adherence to HAART. <i>Journal of the National Medical Association</i> , 2004 , 96, 27S-29S	2.3	4
27	Socio-economic- and sex-related disparities in rates of hospital admission among patients with HIV infection in Ontario: a population-based study. <i>Open Medicine</i> , 2012 , 6, e146-54		3
26	Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. <i>Alcohol Research</i> , 2010 , 33, 280-7		53
25	Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. <i>Health Care Financing Review</i> , 2005 , 26, 67-80		3
24	Comorbidities among HIV-infected injection drug users in Chennai, India. <i>Indian Journal of Medical Research</i> , 2008 , 127, 447-52	2.9	25
23	Improving HCV cure rates in HIV-coinfected patients - a real-world perspective. <i>American Journal of Managed Care</i> , 2016 , 22, SP198-204	2.1	8
22	Retention in HIV care: what the clinician needs to know. <i>Topics in Antiviral Medicine</i> , 2011 , 19, 12-6	3.2	34
21	Routine HIV clinic visit adherence in the African Cohort Study.. <i>AIDS Research and Therapy</i> , 2022 , 19, 1	3	1
20	Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2000 , 5, 195-197	1.6	21
19	Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response. <i>Antiviral Therapy</i> , 2001 , 6, 97-103	1.6	19
18	A Rational Approach to the Selection and Sequencing of Nucleoside/Nucleotide Analogues: A New Paradigm. <i>Antiviral Therapy</i> , 2001 , 6, 45-54	1.6	9
17	Combination of Protease Inhibitors for the Treatment of HIV-1-Infected Patients: A Review of Pharmacokinetics and Clinical Experience. <i>Antiviral Therapy</i> , 2002 , 6, 201-229	1.6	40
16	Salvage Therapy with Abacavir in HIV-1-Infected Patients with Previously Documented M184V Mutation: A Possibility of Nrti Recycling. <i>Antiviral Therapy</i> , 2003 , 8, 121-126	1.6	
15	Phenotype or Virtual Phenotype for Choosing Antiretroviral Therapy after Failure: A Prospective, Randomized Study. <i>Antiviral Therapy</i> , 2003 , 8, 577-584	1.6	33
14	Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure. <i>Antiviral Therapy</i> , 2004 , 9, 615-625	1.6	10
13	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. <i>Antiviral Therapy</i> , 2004 , 9, 537-543	1.6	10

12	Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes. <i>Antiviral Therapy</i> , 2004 , 9, 713-719	1.6	81
11	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004 , 9, 263-274	1.6	5
10	Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens. <i>Antiviral Therapy</i> , 2004 , 9, 595-602	1.6	14
9	The Correlation between Plasma Concentrations of Protease Inhibitors, Medication Adherence and Virological Outcome in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2004 , 9, 753-761	1.6	12
8	Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial. <i>Antiviral Therapy</i> , 2006 , 11, 321-327	1.6	9
7	Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2005 , 10, 375-392	1.6	41
6	The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens. <i>Antiviral Therapy</i> , 2005 , 10, 459-467	1.6	10
5	Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome. <i>Antiviral Therapy</i> , 2006 , 11, 553-560	1.6	28
4	The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients. <i>Antiviral Therapy</i> , 2004 , 9, 301-314	1.6	23
3	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005 , 10, 41-52	1.6	8
2	The association of CD4 lymphocyte count with drug hypersensitivity reaction to highly active antiretroviral therapy, trimethoprim sulfamethoxazole, and antitubercular agents in human immunodeficiency virus patients. 2022 , 12,		0
1	Efficacy of an mHealth self-management intervention for persons living with HIV: the WiseApp randomized clinical trial.		1